Introduction Breast cancer is the most common cancer and the second leading cause of
cancer-related death in women worldwide. Despite the early detection of breast cancer and …

Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

Purpose Many patients with hormone receptor–positive (HR+) breast cancer do not adhere
to endocrine therapy (ET), and treatment-related side effects are often discussed by …

Breast cancer is one of the major causes of mortality in women worldwide. The current
treatments available are radiation therapy (RT), surgery, endocrine (hormone) therapy (ET) …

Chemotherapy is an important tool for the management of solid tumors including breast
cancers (BC). Its neo-adjuvant and adjuvant use is important for shrinking tumor size and …

Background: Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and
mortality of women with hormone-receptor-positive tumors, but poor adherence remains a …

Endocrine therapy is currently the main therapeutic approach for estrogen receptor-positive
(ER+) breast cancer, the most frequent subtype of breast cancer in women worldwide. For …

Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in
hormone receptor positive (HR+) breast cancer (BC). Thus, endocrine therapy (ET) alone or …

Breast cancer (BCa) is one of the most predominantly diagnosed cancers in women.
Notably, 70% of BCa diagnoses are Estrogen Receptor α positive (ERα+) making it a critical …

Cancer is the most common cause of mortality worldwide. There is dire need of modern
strategies—such as surface modification of nanocarriers—to combat this global illness …